Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966199 | 0.81 | EPHX1 (0.37) | ALDH1A1KDM4EKMT2ASMN1; SMN2TDP1 | |
| SCHEMBL962061 | 0.80 | THRB (0.40) | ALDH1A1LMNAKDM4EGAAKMT2A | |
| SCHEMBL963002 | 0.74 | — | — | |
| SCHEMBL965469 | 0.73 | MEN1 (0.48) | ALDH1A1LMNAKDM4EKMT2ASMN1; SMN2 | |
| SCHEMBL4136408 | 0.72 | THRB (0.44) | ALDH1A1LMNAKDM4EGAAKMT2A | |
| SCHEMBL1693036 | 0.68 | — | — | |
| SCHEMBL482045 | 0.68 | — | — | |
| SCHEMBL16440063 | 0.68 | L3MBTL1 (0.45) | HPGDL3MBTL1ALDH1A1LMNAAGTR1 | |
| SCHEMBL16440064 | 0.68 | L3MBTL1 (0.45) | HPGDL3MBTL1ALDH1A1LMNAAGTR1 | |
| SCHEMBL2334924 | 0.67 | CYP2D6 (0.40) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2454270-A2 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | Hetero Research Foundation (IN) | 2012-05-23 | — | — | EP | disclosed |
| WO-2011007230-A2 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | WO | disclosed |
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | HETERO RESEARCH FOUNDATION (IN) | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015196-A1 | LUPEOL-TYPE TRITERPENE DERIVATIVES AS ANTIVIRALS | MAVS, IRF3, LSS | HPGD 2521/4885L3MBTL1 1560/4885ALDH1A1 4653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.